Valuation : ProQR Therapeutics N.V.

Market Cap 292M 251M 237M 216M 404M 27.58B 405M 2.79B 1.08B 14.15B 1.1B 1.07B 45.59B P/E 2026 *
-4.37x
P/E 2027 * -3.81x
Enterprise Value 292M 251M 237M 216M 404M 27.58B 405M 2.79B 1.08B 14.15B 1.1B 1.07B 45.59B EV / Sales 2026 *
14.1x
EV / Sales 2027 * 15.7x
Free-Float
81.49%
Yield 2026 *
-
Yield 2027 * -
1 day-0.96%
1 week-9.61%
Current month-2.82%
1 month+5.08%
3 months+38.00%
6 months+22.49%
Current year+2.48%
1 week 2.06
Extreme 2.06
2.29
1 month 1.79
Extreme 1.79
2.46
Current year 1.33
Extreme 1.33
2.46
1 year 1.33
Extreme 1.33
3.1
3 years 1.07
Extreme 1.07
4.62
5 years 0.53
Extreme 0.53
9.09
10 years 0.53
Extreme 0.53
24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 62 2021-12-31
Chief Executive Officer 43 2012-02-20
Director of Finance/CFO 50 2025-04-13
Director TitleAgeSince
Director/Board Member 43 -
Director/Board Member 62 -
Chairman 69 2024-05-21
Date Insider Type Main position Quantity % Market Cap. Importance
7/31/26 Buy

Founder

200,000 0.1448%
7/17/26 Buy

Director

150,000 0.1424%
7/9/26 Buy

Founder

150,000 0.1424%
Change 5-day change 1-year change 3-year change Capi.($)
-0.96%-9.61%-15.51%+29.38% 292M
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
+0.86%+1.65%-7.74%-14.95% 26.06B
-3.00%-2.90%+33.13%+12.54% 25.74B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -1.34%-0.73%+36.88%+162.76% 27.94B
Weighted average by Cap. -1.52%+0.17%+38.32%+137.24%

Financials

2026 *2027 *
Net sales 20.66M 17.78M 16.73M 15.28M 28.58M 1.95B 28.66M 198M 76.69M 1B 77.58M 75.88M 3.22B 18.66M 16.06M 15.11M 13.8M 25.82M 1.76B 25.89M 179M 69.28M 904M 70.08M 68.55M 2.91B
Net income -58.49M -50.33M -47.36M -43.26M -80.93M -5.52B -81.15M -560M -217M -2.83B -220M -215M -9.13B -73.86M -63.56M -59.8M -54.63M -102M -6.97B -102M -707M -274M -3.58B -277M -271M -11.53B
Net Debt - -
Logo ProQR Therapeutics N.V.
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Employees
187
Date Price Change Volume
26-09-04 US$2.070 -0.96% 368,464
26-09-03 US$2.090 -2.79% 697,400
26-09-02 US$2.150 +1.42% 389,554
26-09-01 US$2.120 -0.47% 569,343
26-08-31 US$2.130 -6.99% 943,523
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.070USD
Average target price
8.222USD
Spread / Average Target
+297.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRQR Stock